Renfu Medicine's Omega-3-Ethyl Acid Obtained FDA Approval Number

Pharmaceutical Network, June 17 - Renfu Pharmaceuticals announced on June 16 that the holding subsidiary Puracap Pharmaceutical LLC (hereinafter referred to as "U.SPuke") has recently received the U.SFDA approval number for omega-3-ethyl acid ester softgelsOmega-3-ethyl acid softgels are mainly used to reduce hypertriglyceride and triglycerideswith a low-fatdietAccording to IMS, thedrugtotal sales in the U.Smarket in 2019 will be about $120 million, with major manufacturers including Strides, Apotex, Amneal and TevaPuk filed an ANDA application for Omega-3-ethyl acid softgels in 2017 with a cumulative research and development investment of approximately $1.2 millionThis omega-3-ethyl acid softgel obtained the U.SFDA approval number, marking the U.SPuke in the U.Smarket sales of the product eligibilityAccording to the website of the State Drug Administration, there is no domestic production of omega-3-ethyl acid ethyl acetate preparations approved for sale, according to insight statistics, Abbott Trade (Shanghai) Co., Ltd., Sichuan Guofor pharmaceutical Co., Ltd., Chengdu ShengdiPharmaceuticalCo., Ltdhas submitted the drug's listing application